On Jan. 5, 2021, Humanigen announced that target enrollment in the Phase 2/3 ACTIV-5/BET-B study had been achieved.

The study, sponsored by the National Institute of Allergy and Infectious Diseases, enrolled over 400 patients in the primary analysis population at approximately 55 recruiting clinical sites including international sites. The ACTIV-5/BET-B study was designed to align with the Companyﾒs Phase 3 study of its lead investigational product candidate, lenzilumab, in hospitalized patients with COVID-19 (ﾓLIVE-AIRﾔ), results of which recently were published in Lancet Respiratory Medicine.